Clinical trial
Efficacy and Safety of PegIFN +/- FTC / TDF to Treat Chronic Hepatitis B in…
NCT00221286 · University Hospital, Bonn, Other · Terminated
Key facts
| NCT number | NCT00221286 |
|---|---|
| Title | Efficacy and Safety of PegIFN +/- FTC / TDF to Treat Chronic Hepatitis B in HIV-Coinfected Patients |
| Official title | Pegylated Interferon Alfa-2a Versus Emtricitabine / Tenofovir +/- Pegylated Interferon Alfa-2a for the Treatment of Chronic HBe-Ag Positive Hepatitis B Infection in HIV-Coinfected Patients - the PEGPLUS Trial |
| Lead sponsor | University Hospital, Bonn, Other |
| Collaborators | Hoffmann-La Roche Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis B, HIV Infections |
| Intervention type | Drug |
| Interventions | pegylated interferon alfa-2a, tenofovir DF / emtricitabine combination therapy, pegIFN / TDF / FTC combination therapy |
| Enrollment | 2 |
| Start date | Sep 1, 2004 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | Feb 18, 2009 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: